/Agilent%20Technologies%20Inc_%20HQ%20sign-by%20hapabapa%20via%20iStock.jpg)
Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, provides application focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at $39.6 billion by market cap, the company offers electronic and bio-analytical measurement, semiconductor, and board testing. The global leader in analytical and clinical laboratory technologies is expected to announce its fiscal first-quarter earnings for 2026 in the near future.
Ahead of the event, analysts expect A to report a profit of $1.37 per share on a diluted basis, up 4.6% from $1.31 per share in the year-ago quarter. The company has surpassed or met Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect A to report EPS of $5.93, up 6.1% from $5.59 in fiscal 2025. Its EPS is expected to rise 10.3% year over year to $6.54 in fiscal 2027.
A stock has underperformed the S&P 500 Index’s ($SPX) 13.3% gains over the past 52 weeks, with shares down 7.8% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund’s (XLV) 10.9% gains over the same time frame.
On Nov. 25, 2025, A shares closed up more than 2% after reporting its Q4 results. Its adjusted EPS of $1.59 met Wall Street expectations. The company’s revenue was $1.9 billion, exceeding Wall Street forecasts of $1.8 billion. Agilent expects full-year adjusted EPS in the range of $5.86 to $6, and revenue ranging from $7.3 billion to $7.4 billion.
Analysts’ consensus opinion on A stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 18 analysts covering the stock, 12 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and five give a “Hold.” A’s average analyst price target is $170.67, indicating a potential upside of 25.6% from the current levels.
